Literature DB >> 24142094

Pharmacogenetics in schizophrenia: a review of clozapine studies.

Fabiana Barzotti Kohlrausch1.   

Abstract

OBJECTIVES: Clozapine is quite effective to treat schizophrenia, but its use is complicated by several factors. Although many patients respond to antipsychotic therapy, about 50% of them exhibit inadequate response, and ineffective medication trials may entail weeks of unremitted illness, potential adverse drug reactions, and treatment nonadherence. This review of the literature sought to describe the main pharmacogenetic studies of clozapine and the genes that potentially influence response to treatment with this medication in schizophrenics.
METHODS: We searched the PubMed database for studies published in English in the last 20 years using keywords related to the topic. RESULTS AND
CONCLUSIONS: Our search yielded 145 studies that met the search and selection criteria. Of these, 21 review articles were excluded. The 124 studies included for analysis showed controversial results. Therefore, efforts to identify key gene mechanisms that will be useful in predicting clozapine response and side effects have not been fully successful. Further studies with new analysis approaches and larger sample sizes are still required.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24142094     DOI: 10.1590/1516-4446-2012-0970

Source DB:  PubMed          Journal:  Braz J Psychiatry        ISSN: 1516-4446            Impact factor:   2.697


  5 in total

1.  Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine.

Authors:  Danielle L Taylor; Arun K Tiwari; Jeffrey A Lieberman; Steven G Potkin; Herbert Y Meltzer; Joanne Knight; Gary Remington; Daniel J Müller; James L Kennedy
Journal:  Mol Neuropsychiatry       Date:  2016-10-12

Review 2.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics.

Authors:  John Lally; Fiona Gaughran; Philip Timms; Sarah R Curran
Journal:  Pharmgenomics Pers Med       Date:  2016-11-07

3.  »Treatment Resistance« Enigma Resolved by Pharmacogenomics - A Case Study of Clozapine Therapy in Schizophrenia.

Authors:  Nadja P Marić; Slobodanka Pejović Nikolić; Ivana Buzadžić; Milica Jovičić; Sanja Andrić; Marina Mihaljević; Zorana Pavlović
Journal:  J Med Biochem       Date:  2015-03-03       Impact factor: 3.402

Review 4.  Clozapine: An Updated Overview of Pharmacogenetic Biomarkers, Risks, and Safety-Particularities in the Context of COVID-19.

Authors:  Ana Miruna Dragoi; Ioana Radulescu; Bogdana Adriana Năsui; Anca Lucia Pop; Valentin Nicolae Varlas; Simona Trifu
Journal:  Brain Sci       Date:  2020-11-11

5.  Tubulin/microtubules as novel clozapine targets.

Authors:  Mizuki Hino; Takeshi Kondo; Yasuto Kunii; Junya Matsumoto; Akira Wada; Shin-Ichi Niwa; Mitsutoshi Setou; Hirooki Yabe
Journal:  Neuropsychopharmacol Rep       Date:  2021-12-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.